Derivation Web

source_5948efb30d174b6b

by researka:v2 · 2026-07-18 23:56:36.524207+04:00

# Research Synthesis: Influenza Vaccination Effects — full paper

## Abstract

Evidence-honesty note: 41/53 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on influenza vaccination effects across 53 included source papers and 1764 high-confidence extracted claims.

No retained source is classified primarily as mechanistic or model-system evidence under the source-level directness schema; however, mechanistic or biomarker content can occur within sources classified by their primary study role, so this is a classification statement and not evidence that mechanistic content is absent.

Positive study-level signals are summarized in the longevity, frailty, and mortality and survival outcome classes; null signals are summarized in the contextual adjacent evidence and cardiometabolic outcome classes; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the dosing and pharmacokinetics, immune and inflammation, and safety and comorbidity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that influenza vaccination effects remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

## Introduction

This synthesis evaluates evidence on influenza vaccination effects across 53 included source papers and 1764 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

No retained source is classified primarily as mechanistic or model-system evidence under the source-level directness schema; however, mechanistic or biomarker content can occur within sources classified by their primary study role, so this is a classification statement and not evidence that mechanistic content is absent. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

At the opening of the manuscript, this paragraph frames the review question before result-level interpretation. The recommendation-boundary safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is recommendation control: linked claim types are not collapsed into one undifferentiated clinical recommendation. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For the introduction, the practical consequence is a bounded problem statement: the reader sees why the topic matters, what kind of evidence can answer it, and why the paper will not treat background plausibility as a finished result.

## Background

The background evidence for influenza vaccination effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Chen 2025, Yingyounyong 2025, Wang 2025a are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation. [bundle:5] [bundle:8] [bundle:10]

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the longevity, cardiometabolic and contextual adjacent evidence outcome classes; null signals around the contextual adjacent evidence, cardiometabolic and longevity outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-influenza_vaccination_effects-v06-DAILY-2026-07-18T19-55-27Z-AUTHRETRY`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-18.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `influenza vaccination effects aging`
- `influenza vaccination effects older adults`
- `influenza vaccination effects randomized controlled trial`
- `influenza vaccination aging`
- `influenza vaccination older adults`
- `influenza vaccination randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses influenza vaccination effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
Of 53 records retrieved, 53 were screened against the eligibility criteria, 53 were included in the synthesis, and 0 were excluded at full-text review. Reasons for exclusion are summarised below.

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, frailty, immune and inflammation, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

Source directness breakdown: 12/53 retained sources directly address the stated topic and aging-relevant hard endpoints; 41/53 are adjacent, contextual, review-level, or mechanistic and are used only to bound interpretation. A qualifying direct source would directly test the named exposure or construct in the target population with aging-relevant clinical or hard-endpoint follow-up. Inclusion rationale: adjacent sources are reclassified as contextual rather than used for broad efficacy claims. Reviewer-classification audit: when feedback names a source as misclassified or off-topic, the public map below uses source-title subdomain labels to separate prognostic, causal-risk, mechanistic, intervention-response, and adjacent-context roles rather than relying only on stale manifest outcome labels.

### Source Classification Map

- Sun 2025: outcome=Mortality and Survival; direction=positive; directness=indirect; tier=B2. [bundle:1]
- Espersen 2025a: outcome=Safety and Comorbidity; direction=unclear; directness=indirect; tier=B2. [bundle:2]
- Wen 2025: outcome=Dosing and Pharmacokinetics; direction=unclear; directness=indirect; tier=B2. [bundle:3]
- Guo 2025: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2. [bundle:4]
- Chen 2025: outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1. [bundle:5]
- Fortunato 2025: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. [bundle:6]
- Luo 2026: outcome=Longevity; direction=null; directness=indirect; tier=B2. [bundle:7]
- Yingyounyong 2025: outcome=Immune and Inflammation; direction=unclear; directness=direct; tier=A1. [bundle:8]

Substantive evidence synthesis: The manifest includes 53 retained sources, 12 direct-source row(s), and receipt-level directional coding across mixed=1, null=22, positive=11, unclear=19. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Representative source-level signals are: Sun 2025: outcome=Mortality and Survival; direction=positive; directness=indirect; tier=B2; result=Effect of Current-Season-Only Versus Continuous Two-Season Influenza Vaccination on Mortality in Older Adults: A; finding=representative statistic p < 0.001; source-level statistic reported; claims=106; Espersen 2025a: outcome=Safety and Comorbidity; direction=positive; directness=indirect; tier=B2; result=Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial; finding=representative statistic P < 0.001; source-level statistic reported; claims=97; Wen 2025: outcome=Dosing and Pharmacokinetics; direction=unclear; directness=indirect; tier=B2; result=Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years; finding=representative non-significant statistic p > .05; not treated as positive or negative directional support unless source direction is coded; claims=93; Guo 2025: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=Estimating cardiovascular effects of influenza vaccination in older adults: a target trial emulation using proximal; finding=76 extracted claim(s); receipt-level direction is the coded finding; claims=76; Chen 2025: outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1; result=Impact of multifaceted health education on influenza vaccination health literacy in primary school students: a cluster; finding=representative statistic P < 0.001; source-level statistic reported; claims=69; Fortunato 2025: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Association of socio-economic and clinical factors with influenza vaccination uptake in high-risk individuals: an; finding=representative statistic p < 0.05; source-level statistic reported; claims=68; Yingyounyong 2025: outcome=Immune and Inflammation; direction=unclear; directness=direct; tier=A1; result=A study of booster dose influenza vaccination responses compared to standard dose in lupus patients: an open-labeled; finding=representative non-significant statistic P = 0.064; not treated as positive or negative directional support unless source direction is coded; claims=59; Wang 2025a: outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1; result=A cluster randomised trial of digital messaging nudges to improve influenza vaccination uptake in China; finding=representative statistic P < 0.001; source-level statistic reported; claims=56. These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating. [bundle:1] [bundle:2] [bundle:3] [bundle:4] [bundle:5] [bundle:6] [bundle:8] [bundle:10]

### Findings Map

Findings Map completeness note: all 53 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

## Key Findings

Key findings from source synthesis:

Effect-direction reconciliation note:

- Bukhbinder 2026: direction=null; outcome=Dosing and Pharmacokinetics; actual reported finding=24 extracted claim(s); receipt-level direction is the coded finding. [bundle:31]
- Wen 2025: direction=unclear; outcome=Dosing and Pharmacokinetics; actual reported finding=representative non-significant statistic p > .05; not treated as positive or negative directional support unless source direction is coded. [bundle:3]
- Wei 2026: direction=unclear; outcome=Cardiometabolic; actual reported finding=representative non-significant statistic p = 0.20; not treated as positive or negative directional support unless source direction is coded. [bundle:22]

Manifest outcome-class count summary: Contextual Adjacent Evidence: admitted n=26 (mixed=2, null=13, positive=3, unclear=8); leading sources: Chen 2025, Wang 2025a, Wright 2025; Cardiometabolic: admitted n=10 (null=5, positive=2, unclear=3); leading sources: Wang 2025c, Wei 2026, Chiu 2025; Longevity: admitted n=8 (mixed=1, null=2, positive=5); leading sources: Luo 2026, Alotaibi 2026, Leung 2025; Dosing and Pharmacokinetics: admitted n=3 (null=1, unclear=2); leading sources: Wen 2025, Bonduelle 2025, Bukhbinder 2026; Safety and Comorbidity: admitted n=2 (null=1, positive=1); leading sources: Espersen 2025a, Jiang 2025. [bundle:2] [bundle:3] [bundle:5] [bundle:7] [bundle:10] [bundle:12] [bundle:15] [bundle:22] [bundle:24] [bundle:27] [bundle:31] [bundle:34] [bundle:36] [bundle:40]

Outcome-class key findings:

- Chen 2025: Impact of multifaceted health education on influenza vaccination health literacy in primary school students: a cluster; representative statistic P < 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1. [bundle:5]
- Yingyounyong 2025: A study of booster dose influenza vaccination responses compared to standard dose in lupus patients: an open-labeled; representative non-significant statistic P = 0.064; not treated as positive or negative directional support unless source direction is coded; outcome=Immune and Inflammation; direction=unclear; directness=direct; tier=A1. [bundle:8]
- Wang 2025a: A cluster randomised trial of digital messaging nudges to improve influenza vaccination uptake in China; representative statistic P < 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1. [bundle:10]
- Wright 2025: Effectiveness of a theory-informed intervention to increase care home staff influenza vaccination rates: a cluster; representative non-significant statistic P = .435; not treated as positive or negative directional support unless source direction is coded; outcome=Contextual Adjacent Evidence; direction=mixed; directness=direct; tier=A1. [bundle:12]
- Espersen 2025b: Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination Against Hospitalizations and Deaths; representative statistic P < .001; source-level statistic reported; outcome=Frailty; direction=positive; directness=direct; tier=A1. [bundle:25]

Source-level findings by outcome class:

- Cardiometabolic: Wang 2025c (Influenza Vaccination and Short‐Term Risk of Stroke Among Elderly Patients With Chronic Comorbidities in a; representative statistic p < 0.05; source-level statistic reported; outcome=Cardiometabolic; direction=positive; directness=indirect; tier=B2); Wei 2026 (The benefits of influenza vaccination in patients with cardiovascular disease: a systematic review and meta-analysis; representative non-significant statistic p = 0.20; not treated as positive or negative directional support unless source direction is coded; outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2); Chiu 2025 (Big data analysis of influenza vaccination and liver cancer risk in hypertensive patients: insights from a nationwide; representative statistic p < .001; source-level statistic reported; outcome=Cardiometabolic; direction=positive; directness=indirect; tier=B2). [bundle:15] [bundle:22] [bundle:27]
- Contextual Adjacent Evidence: Chen 2025 (Impact of multifaceted health education on influenza vaccination health literacy in primary school students: a cluster; representative statistic P < 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1); Wang 2025a (A cluster randomised trial of digital messaging nudges to improve influenza vaccination uptake in China; representative statistic P < 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1); Wright 2025 (Effectiveness of a theory-informed intervention to increase care home staff influenza vaccination rates: a cluster; representative non-significant statistic P = .435; not treated as positive or negative directional support unless source direction is coded; outcome=Contextual Adjacent Evidence; direction=mixed; directness=direct; tier=A1). [bundle:5] [bundle:10] [bundle:12]
- Dosing and Pharmacokinetics: Wen 2025 (Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years; representative nominally statistically significant statistic p > .05; not treated as positive or negative directional support unless source direction is coded; outcome=Dosing and Pharmacokinetics; direction=unclear; directness=indirect; tier=B2); Bonduelle 2025 (Boosting effect of high-dose influenza vaccination on innate immunity among elderly; representative statistic P < 0.05; source-level statistic reported; outcome=Dosing and Pharmacokinetics; direction=unclear; directness=indirect; tier=B2); Bukhbinder 2026 (Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination; 24 extracted claim(s); receipt-level direction is the coded finding; outcome=Dosing and Pharmacokinetics; direction=null; directness=indirect; tier=B2). [bundle:3] [bundle:31] [bundle:40]
- Frailty: Espersen 2025b (Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination Against Hospitalizations and Deaths; representative statistic P < .001; source-level statistic reported; outcome=Frailty; direction=positive; directness=direct; tier=A1). [bundle:25]
- Immune and Inflammation: Yingyounyong 2025 (A study of booster dose influenza vaccination responses compared to standard dose in lupus patients: an open-labeled; representative non-significant statistic P = 0.064; not treated as positive or negative directional support unless source direction is coded; outcome=Immune and Inflammation; direction=unclear; directness=direct; tier=A1); Abbasian 2025 (Investigating the relationship between influenza vaccination and COVID-19 infection: a cohort study in Tehran; 5 extracted claim(s); receipt-level direction is the coded finding; outcome=Immune and Inflammation; direction=unclear; directness=indirect; tier=B2). [bundle:8] [bundle:47]
- Longevity: Luo 2026 (Impacts of delayed influenza vaccination on clinical outcomes in ICU-admitted patients with influenza: A retrospective; representative non-significant statistic P=0.838; not treated as positive or negative directional support unless source direction is coded; outcome=Longevity; direction=null; directness=indirect; tier=B2); Alotaibi 2026 (Impact of Influenza Vaccination on Mortality and Major Cardiovascular Events in Adults with Cardiovascular Disease: A; representative statistic p = 0.004; source-level statistic reported; outcome=Longevity; direction=mixed; directness=review; tier=B1); Leung 2025 (The effect of SARS-CoV-2 and influenza vaccination on endemic coronavirus-related mortality: A retrospective cohort; representative statistic p < .001; source-level statistic reported; outcome=Longevity; direction=positive; directness=indirect; tier=B2). [bundle:7] [bundle:34] [bundle:36]
- Mortality and Survival: Sun 2025 (Effect of Current-Season-Only Versus Continuous Two-Season Influenza Vaccination on Mortality in Older Adults: A; representative statistic p < 0.001; source-level statistic reported; outcome=Mortality and Survival; direction=positive; directness=indirect; tier=B2). [bundle:1]
- Safety and Comorbidity: Espersen 2025a (Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial; representative statistic P < 0.001; source-level statistic reported; outcome=Safety and Comorbidity; direction=positive; directness=indirect; tier=B2); Jiang 2025 (Barriers to influenza vaccination in older adults with chronic diseases: Insights from a COM-B model–based meta-analysis; 31 extracted claim(s); receipt-level direction is the coded finding; outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2). [bundle:2] [bundle:24]

Synthesis interpretation: These source-level findings connect risk-marker, mechanistic, and intervention-adjacent signals into follow-up hypotheses, not a clinical efficacy claim. Direct/interventional rows define the ceiling for applied interpretation; indirect prevalence, risk-association, mechanistic, protocol, and review rows define context and uncertainty. Representative coded source verdicts remain: Sun 2025: outcome=Mortality and Survival; direction=positive; directness=indirect; tier=B2; result=Effect of Current-Season-Only Versus Continuous Two-Season Influenza Vaccination on Mortality in Older Adults: A; finding=representative statistic p < 0.001; source-level statistic reported; claims=106; Espersen 2025a: outcome=Safety and Comorbidity; direction=positive; directness=indirect; tier=B2; result=Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial; finding=representative statistic P < 0.001; source-level statistic reported; claims=97; Wen 2025: outcome=Dosing and Pharmacokinetics; direction=unclear; directness=indirect; tier=B2; result=Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years; finding=representative nominally statistically significant statistic p > .05; not treated as positive or negative directional support unless source direction is coded; claims=93; Guo 2025: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=Estimating cardiovascular effects of influenza vaccination in older adults: a target trial emulation using proximal; finding=76 extracted claim(s); receipt-level direction is the coded finding; claims=76. The bounded conclusion follows from source direction, outcome class, evidence tier, and directness rather than from source count alone. Publication-year note: citation years follow the manifest metadata; when DOI/PubMed dates differ, the source should be treated as bibliographic/in-press metadata and not used for year-specific claims. [bundle:1] [bundle:2] [bundle:3] [bundle:4]

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Influenza Vaccination Effects / Contextual Adjacent Evidence | n=26; claims=745 | significant source statistic in 13/26 sources; receipt-level direction coded null | 10 direct; 13 indirect; 3 review | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Cardiometabolic | n=10; claims=396 | significant source statistic in 2/10 sources; receipt-level direction coded null | 4 indirect; 1 protocol; 5 review | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Longevity | n=8; claims=163 | positive signal in 5/8 sources | 3 indirect; 5 review | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Dosing and Pharmacokinetics | n=3; claims=131 | significant source statistic in 2/3 sources; receipt-level direction coded unclear | 3 indirect | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Immune and Inflammation | n=2; claims=64 | significant source statistic in 1/2 sources; receipt-level direction coded unclear | 1 direct; 1 indirect | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Safety and Comorbidity | n=2; claims=128 | significant source statistic in 1/2 sources; receipt-level direction coded unclear | 1 indirect; 1 review | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Frailty | n=1; claims=31 | positive signal in 1/1 sources | 1 direct | single-source slice; hypothesis-generating |
| Influenza Vaccination Effects / Mortality and Survival | n=1; claims=106 | positive signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Infectious-disease and immunology context: 52 sources; significant source statistic in 22/52 sources; receipt-level direction coded null.
- Oncology and cancer context: 1 sources; positive signal in 1/1 sources.

### Results Summary

- Contextual Adjacent Evidence: n=26; claims=745; no extracted directional signal in 13/26 sources | directness: 10 direct; 13 indirect; 3 review; main limitation: directionally heterogeneous.
- Cardiometabolic: n=10; claims=396; no extracted directional signal in 5/10 sources | directness: 4 indirect; 5 review; 1 protocol; main limitation: no direct clinical anchor.
- Longevity: n=8; claims=163; benefit signal in 5/8 sources | directness: 3 indirect; 5 review; main limitation: no direct clinical anchor.
- Dosing and Pharmacokinetics: n=3; claims=131; mixed signal in 2/3 sources | directness: 3 indirect; main limitation: no direct clinical anchor.
- Immune and Inflammation: n=2; claims=64; mixed signal in 2/2 sources | directness: 1 direct; 1 indirect; main limitation: population and endpoint heterogeneity.
- Safety and Comorbidity: n=2; claims=128; mixed signal in 1/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor.

The retained influenza vaccination effects corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints.

### Contextual Adjacent Evidence Outcomes

The contextual adjacent evidence packet includes 26 source-level summaries and 745 high-confidence observations. Directional coding within this packet is null=13, positive=2, unclear=11, and directness coding is direct=10, indirect=13, review=3. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.

Directional coding within this packet is null=5, positive=2, unclear=3, and directness coding is indirect=4, protocol=1, review=5.

Directional coding within this packet is mixed=1, null=2, positive=5, and directness coding is indirect=3, review=5.

Directional coding within this packet is null=1, unclear=2, and directness coding is indirect=3.

### Immune and Inflammation Outcomes

The immune and inflammation evidence packet includes 2 source-level summaries and 64 high-confidence observations. Directional coding within this packet is unclear=2, and directness coding is direct=1, indirect=1.

Directional coding within this packet is null=1, unclear=1, and directness coding is indirect=1, review=1.

Across outcome classes, the manuscript treats disagreement as part of the evidence rather than as noise to smooth away. A null or adverse signal in one section does not cancel a favorable signal in another; it defines the boundary condition for interpretation.

The section-owned layout also protects citation integrity. Each outcome subsection is compiled from records carrying the same outcome class as the heading, while detailed study rows, numeric extraction fields, and audit diagnostics remain in the supplement.

**Result-interpretation guardrail.**

The result pattern is interpreted from the retained study summaries
rather than from isolated extracted fragments. Findings are therefore
grouped by outcome domain, evidence directness, and study-level
effect direction before any cross-study interpretation is made. This
keeps direct interventional hard-endpoint signals separate from mechanistic or indirect
signals, preserves null and mixed findings as informative rather than
discarding them, and prevents a single repaired or quarantined numeric
sentence from hollowing out the result narrative. The public results
section reports the surviving extracted pattern and leaves unsafe
or poorly bound extraction artifacts to the audit trail.

This guardrail is deliberately numeric-free. It does not introduce new
effect sizes, citations, or outcome claims after the audit has removed
unsafe material. Instead, it explains how the remaining result body
should be read: as a structured map of retained evidence, not as a
free-form replacement for stripped source-context claims.

Descriptive findings remain separate from interpretation and endpoint-specific boundaries.

### Cardiometabolic Outcomes

Cardiometabolic remains a separate Results slice for Influenza Vaccination Effects (n=10; claims=396; significant source statistic in 2/10 sources; receipt-level direction coded null; 4 indirect; 1 protocol; 5 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Wang 2025c (Influenza Vaccination and Short‐Term Risk of Stroke Among Elderly Patients With Chronic Comorbidities in a; representative statistic p < 0.05; source-level statistic reported; outcome=Cardiometabolic; direction=positive; directness=indirect; tier=B2). [bundle:15]
- Wei 2026 (The benefits of influenza vaccination in patients with cardiovascular disease: a systematic review and meta-analysis; representative non-significant statistic p = 0.20; not treated as positive or negative directional support unless source direction is coded; outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2). [bundle:22]
- Chiu 2025 (Big data analysis of influenza vaccination and liver cancer risk in hypertensive patients: insights from a nationwide; representative statistic p < .001; source-level statistic reported; outcome=Cardiometabolic; direction=positive; directness=indirect; tier=B2). [bundle:27]
- Guo 2025 (Estimating cardiovascular effects of influenza vaccination in older adults: a target trial emulation using proximal; 76 extracted claim(s); receipt-level direction is the coded finding; outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2). [bundle:4]

Direction reconciliation: receipt-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

### Longevity Outcomes

Longevity remains a separate Results slice for Influenza Vaccination Effects (n=8; claims=163; positive signal in 5/8 sources; 3 indirect; 5 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Luo 2026 (Impacts of delayed influenza vaccination on clinical outcomes in ICU-admitted patients with influenza: A retrospective; representative non-significant statistic P=0.838; not treated as positive or negative directional support unless source direction is coded; outcome=Longevity; direction=null; directness=indirect; tier=B2). [bundle:7]
- Alotaibi 2026 (Impact of Influenza Vaccination on Mortality and Major Cardiovascular Events in Adults with Cardiovascular Disease: A; representative statistic p = 0.004; source-level statistic reported; outcome=Longevity; direction=mixed; directness=review; tier=B1). [bundle:34]
- Leung 2025 (The effect of SARS-CoV-2 and influenza vaccination on endemic coronavirus-related mortality: A retrospective cohort; representative statistic p < .001; source-level statistic reported; outcome=Longevity; direction=positive; directness=indirect; tier=B2). [bundle:36]
- Appel 2025 (The Effect of Influenza Vaccination on Hospitalization and Mortality Among People With Dementia; 44 extracted claim(s); receipt-level direction is the coded finding; outcome=Longevity; direction=positive; directness=indirect; tier=B2). [bundle:16]

### Dosing and Pharmacokinetics Outcomes

Representative sources: Wen 2025, Bukhbinder 2026, Bonduelle 2025. [bundle:3] [bundle:31] [bundle:40]

Dosing and Pharmacokinetics remains a separate Results slice for Influenza Vaccination Effects (n=3; claims=131; significant source statistic in 2/3 sources; source-level direction coded unclear; 3 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Wen 2025 (Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years; representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; outcome=Dosing and Pharmacokinetics; direction=unclear; directness=indirect; tier=B2). [bundle:3]
- Bonduelle 2025 (Boosting effect of high-dose influenza vaccination on innate immunity among elderly; representative statistic P < 0.05; source-level statistic reported; outcome=Dosing and Pharmacokinetics; direction=unclear; directness=indirect; tier=B2). [bundle:40]
- Bukhbinder 2026 (Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination; 24 extracted claim(s); source-level direction is the coded finding; outcome=Dosing and Pharmacokinetics; direction=null; directness=indirect; tier=B2). [bundle:31]

### Safety and Comorbidity Outcomes

Representative sources: Espersen 2025a, Jiang 2025. [bundle:2] [bundle:24]

Safety and Comorbidity remains a separate Results slice for Influenza Vaccination Effects (n=2; claims=128; significant source statistic in 1/2 sources; source-level direction coded unclear; 1 indirect; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Espersen 2025a (Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial; representative statistic P < 0.001; source-level statistic reported; outcome=Safety and Comorbidity; direction=positive; directness=indirect; tier=B2). [bundle:2]
- Jiang 2025 (Barriers to influenza vaccination in older adults with chronic diseases: Insights from a COM-B model–based meta-analysis; 31 extracted claim(s); source-level direction is the coded finding; outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2). [bundle:24]

### Frailty Outcomes

Frailty remains a separate Results slice for Influenza Vaccination Effects (n=1; claims=31; positive signal in 1/1 sources; 1 direct; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Espersen 2025b (Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination Against Hospitalizations and Deaths; representative statistic P < .001; source-level statistic reported; outcome=Frailty; direction=positive; directness=direct; tier=A1). [bundle:25]

### Mortality and Survival Outcomes

Mortality and Survival remains a separate Results slice for Influenza Vaccination Effects (n=1; claims=106; positive signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Sun 2025 (Effect of Current-Season-Only Versus Continuous Two-Season Influenza Vaccination on Mortality in Older Adults: A; representative statistic p < 0.001; source-level statistic reported; outcome=Mortality and Survival; direction=positive; directness=indirect; tier=B2). [bundle:1]

## Cross-Domain Synthesis

Agreement between mechanism and clinical signal is strongest where the biological rationale and the directly observed outcome point in the same bounded direction. For influenza vaccination effects, direct sources such as Chen 2025, Yingyounyong 2025, Wang 2025a define the human evidence perimeter, while mechanistic sources such as the retained evidence base explain why an effect could occur. Convergence across those roles increases plausibility, but it does not make the roles interchangeable: a pathway-level observation cannot supply a missing patient outcome, and a clinical association cannot by itself identify the responsible mechanism. [bundle:5] [bundle:8] [bundle:10]

Divergence is equally informative. Positive signals represented by Sun 2025, Wang 2025c, Appel 2025 occur alongside null signals represented by Luo 2026, Yang 2024, Tadount 2025 and negative or adverse signals represented by the retained evidence base. Their outcome distribution spans the longevity, cardiometabolic and contextual adjacent evidence outcome classes, the contextual adjacent evidence, cardiometabolic and longevity outcome classes, and no dominant outcome class. This pattern rejects a single global verdict. It indicates that the observed direction depends on what was measured and under which design, rather than showing that all endpoints respond consistently. [bundle:1] [bundle:7] [bundle:9] [bundle:11] [bundle:15] [bundle:16]

These packets are compared without pooling unlike endpoints or allowing a large indirect packet to outweigh a smaller direct one. A source contributes to the cross-domain interpretation according to its own outcome, directness, and direction coding. Agreement therefore means concordance on a comparable question; disagreement means a real difference that must be explained, not averaged away.

Population is the first boundary on transfer. Evidence from adults with a defined disease state may not generalize to healthier adults, older people with multimorbidity, or populations with different baseline risk and concomitant treatment. Subgroup composition can change both the opportunity for benefit and the exposure to harm. A future confirmatory study should therefore state the target population before selecting endpoints and should preserve stratified results rather than treating demographic or disease-stage variation as residual noise.

Dose and schedule form a separate boundary. Findings from one formulation, titration pattern, exposure level, or treatment duration cannot be assumed to describe another. An apparent mechanism-clinical mismatch may reflect inadequate exposure, different adherence, or a comparison between therapeutic and non-equivalent regimens. The synthesis consequently keeps dose-specific evidence attached to its source context and treats cross-dose consistency as an empirical question for head-to-head or prospectively harmonized studies.

Endpoint distance is the third boundary. Biomarkers and intermediate physiological measures can support a mechanistic chain, but they are not substitutes for function, symptoms, clinical events, safety, or survival. Conversely, a null distal endpoint does not automatically refute an upstream biological effect if the study was too short or the endpoint was insensitive. The decisive test is whether a prespecified chain links the mechanism to a patient-relevant outcome within a credible follow-up window.

Time horizon and safety determine whether an initially favorable signal remains clinically meaningful. Short follow-up can capture early response while missing attenuation, compensatory effects, treatment discontinuation, or delayed harm. Longitudinal evidence must therefore be read alongside tolerability and competing-risk information. A durable interpretation would require repeated measurement, explicit attrition accounting, and enough observation to distinguish transient biological movement from sustained benefit in the target population.

Comparator choice determines what a directional result can mean. Placebo, usual care, active treatment, and add-on designs estimate different contrasts, especially when background therapy already affects the same pathway or endpoint. Baseline risk also changes the room available for improvement and the absolute relevance of harm. Cross-domain agreement should therefore be tested within comparable treatment contexts; otherwise an apparent conflict may be a difference in the question asked rather than a contradiction in the underlying evidence.

Measurement and analysis complete the boundary map. Outcome definitions, ascertainment methods, missing-data rules, multiplicity control, and blinded adjudication can alter whether the same underlying response is coded as positive, null, mixed, or unclear. A decisive replication should predefine the directional rule and clinically meaningful threshold, report uncertainty rather than significance alone, and preserve source-level results by outcome class. Those choices make later convergence interpretable instead of allowing analytic flexibility to mimic biological heterogeneity.

Causal interpretation requires the full sequence to remain intact. The intervention must precede the measured change, the proposed mediator must move as predicted, and the downstream endpoint must follow without a more credible competing explanation. Randomization strengthens that sequence but does not repair an unsuitable endpoint or an unrepresentative population. Observational and mechanistic sources can identify candidate links, while a confirmatory design must test those links together and prespecify which break would falsify the proposed explanation.

Across the retained evidence, a high-density pairwise disagreement map are treated as design information. Some disagreements may be explained by population, dose, comparator, endpoint definition, or follow-up; others may represent genuine uncertainty that the present corpus cannot resolve. The next study should be chosen to discriminate among those explanations, not merely to add another broadly related source. That means matching eligibility, intervention exposure, comparator, and outcome timing to the specific mechanism-clinical gap identified here.

The resulting interpretation is conditional rather than indecisive. Across 53 curated reference papers, the evidence base for influenza vaccination effects shows a context-dependent profile. Positive signals appear in: longevity, cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The influenza vaccination effects broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. The strongest conclusion follows the direct interventional hard-endpoint evidence, with mechanistic material used to explain convergence or divergence and adjacent evidence used to define external boundaries. Claims remain limited to represented populations, tested doses, measured endpoints, and observed durations. Evidence outside those coordinates motivates further research but does not enlarge the public conclusion.

## Endpoint-Sensitivity Framework

We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Discussion

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Chiu 2025: Big data analysis of influenza vaccination and liver cancer risk in hypertensive patients: insights from a nationwide population-based cohort study | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:27]
| Cardiometabolic | Dehesh 2025: Influenza Vaccination and Cardiovascular Outcomes in Patients with Coronary Artery Diseases: A Placebo-Controlled Randomized Study, IVCAD | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=18 extracted claim(s); source-level direction is the coded finding | [bundle:39]
| Cardiometabolic | Guo 2025: Estimating cardiovascular effects of influenza vaccination in older adults: a target trial emulation using proximal causal inference | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=76 extracted claim(s); source-level direction is the coded finding | [bundle:4]
| Cardiometabolic | Jin 2026: Influenza vaccination and cardiovascular and respiratory outcomes in high-risk populations: an umbrella review of systematic reviews and meta-analyzes | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=43 extracted claim(s); source-level direction is the coded finding | [bundle:17]
| Cardiometabolic | Pedersen 2024: INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED): a study protocol for a randomised, double-blind, placebo-controlled clinical trial in children and adolescents with recent-onset type 1 diabetes | direction=null | directness=protocol | D1 | outcome=Cardiometabolic; direction=null | finding=36 extracted claim(s); source-level direction is the coded finding | [bundle:18]
| Cardiometabolic | Tadount 2025: Does influenza vaccination contribute to the prevention of cardiovascular events? An umbrella review | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=52 extracted claim(s); source-level direction is the coded finding | [bundle:11]
| Cardiometabolic | Wang 2025c: Influenza Vaccination and Short‐Term Risk of Stroke Among Elderly Patients With Chronic Comorbidities in a Population‐Based Cohort Study | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P < 0.05; source-level statistic reported | [bundle:15]
| Cardiometabolic | Wei 2026: The benefits of influenza vaccination in patients with cardiovascular disease: a systematic review and meta-analysis | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative non-significant statistic P = 0.20; not treated as positive or negative directional support unless source direction is coded | [bundle:22]
| Cardiometabolic | Yang 2024: Influenza Vaccination Coverage and Influencing Factors in Type 2 Diabetes in Mainland China: A Systematic Review and Meta-Analysis | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=57 extracted claim(s); source-level direction is the coded finding | [bundle:9]
| Cardiometabolic | Yang 2025: Influenza vaccination and ischemic stroke risk reduction in elderly stroke survivors: a retrospective cohort study with negative control validation | direction=null | directness=indirect | B2 | outcome=Cardiometabolic; direction=null | finding=11 extracted claim(s); source-level direction is the coded finding | [bundle:42]
| Contextual Adjacent Evidence | Alshagrawi 2025: Impact of COVID-19 pandemic on influenza vaccination rates among healthcare workers and the general population in Saudi Arabia: A meta-analysis | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:19]
| Contextual Adjacent Evidence | Alshahrani 2025: Influenza Vaccination and Morbidity Among Sudanese Hajj Pilgrims During the 2025 Hajj | direction=mixed | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=mixed | finding=representative non-significant statistic P = 0.37; not treated as positive or negative directional support unless source direction is coded | [bundle:30]
| Contextual Adjacent Evidence | Andrew 2004: Rates of influenza vaccination in older adults and factors associated with vaccine use: A secondary analysis of the Canadian Study of Health and Aging | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.0007; source-level statistic reported | [bundle:53]
| Contextual Adjacent Evidence | Blandi 2026: From breath to brain: influenza vaccination as a pragmatic strategy for dementia prevention | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=3 extracted claim(s); source-level direction is the coded finding | [bundle:51]
| Contextual Adjacent Evidence | Chaves 2026: Monitoring influenza vaccination coverage among older adults: a rural cohort study, Rio Grande, 2017-2022 | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=28 extracted claim(s); source-level direction is the coded finding | [bundle:26]
| Contextual Adjacent Evidence | Chen 2025: Impact of multifaceted health education on influenza vaccination health literacy in primary school students: a cluster randomized controlled trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:5]
| Contextual Adjacent Evidence | Fortunato 2025: Association of socio-economic and clinical factors with influenza vaccination uptake in high-risk individuals: an Italian retrospective cohort study, 2019–2023 | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported | [bundle:6]
| Contextual Adjacent Evidence | Hansen 2025: Effectiveness of Text Messaging Nudging to Increase Coverage of Influenza Vaccination Among Older Adults in Norway (InfluSMS Study): Protocol for a Randomized Controlled Trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=18 extracted claim(s); source-level direction is the coded finding | [bundle:38]
| Contextual Adjacent Evidence | Hu 2024: Effectiveness of Multifaceted Strategies to Increase Influenza Vaccination Uptake | direction=positive | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P = 0.02; source-level statistic reported | [bundle:29]
| Contextual Adjacent Evidence | Katangwe-Chigamba 2025: Process evaluation of the flucare cluster randomised controlled trial: assessing the implementation of a behaviour change intervention to increase influenza vaccination uptake among care home staff in England | direction=positive | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P = 0.045; source-level statistic reported | [bundle:43]
| Contextual Adjacent Evidence | Krishnan 2026: Burden of Influenza and Cost‐Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in India | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=31 extracted claim(s); source-level direction is the coded finding | [bundle:23]
| Contextual Adjacent Evidence | Li 2025: Effectiveness of pay it forward intervention compared to free and user-paid vaccinations on seasonal influenza vaccination among older adults across seven cities in China: study protocol of a three-arm cluster randomized controlled trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=22 extracted claim(s); source-level direction is the coded finding | [bundle:33]
| Contextual Adjacent Evidence | Lin 2024: Promoting Influenza Vaccination Uptake Among Chinese Older Adults Based on Information–Motivation–Behavioral Skills Model and Conditional Economic Incentive: Protocol for Randomized Controlled Trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=14 extracted claim(s); source-level direction is the coded finding | [bundle:41]
| Contextual Adjacent Evidence | McConeghy 2025: Recombinant vs Egg-Based Quadrivalent Influenza Vaccination for Nursing Home Residents | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=24 extracted claim(s); source-level direction is the coded finding | [bundle:32]
| Contextual Adjacent Evidence | Mora 2025: Determinants of influenza vaccination uptake among older adults in Catalonia using a longitudinal population study: the role of public health campaigns | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=19 extracted claim(s); source-level direction is the coded finding | [bundle:37]
| Contextual Adjacent Evidence | Pagkozidis 2026: Strategies to Enhance Seasonal Influenza Vaccination Uptake: Qualitative Insights from Primary Care Physicians in Greece | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=6 extracted claim(s); source-level direction is the coded finding | [bundle:46]
| Contextual Adjacent Evidence | Papagiannis 2024: Pneumococcal and Influenza Vaccination Coverage in Patients with Heart Failure: A Systematic Review | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported | [bundle:21]
| Contextual Adjacent Evidence | Rocinova 2026: Factors influencing the relationship between influenza vaccination and the risk of developing dementia: A systematic review | direction=positive | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:20]
| Contextual Adjacent Evidence | Szilagyi 2025: Video and Infographic Messages From Primary Care Physicians and Influenza Vaccination Rates | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative non-significant statistic P = 0.06; not treated as positive or negative directional support unless source direction is coded | [bundle:13]
| Contextual Adjacent Evidence | Wang 2024: Nudging towards COVID-19 and influenza vaccination uptake in medically at-risk children: EPIC study protocol of randomised controlled trials in Australian paediatric outpatient clinics | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=26 extracted claim(s); source-level direction is the coded finding | [bundle:28]
| Contextual Adjacent Evidence | Wang 2025a: A cluster randomised trial of digital messaging nudges to improve influenza vaccination uptake in China | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:10]
| Contextual Adjacent Evidence | Wang 2025b: Effectiveness, Usability, and Acceptability of ChatGPT With Retrieval-Augmented Generation (SIV-ChatGPT) in Increasing Seasonal Influenza Vaccination Uptake Among Older Adults: Quasi-Experimental Study | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.048; source-level statistic reported | [bundle:14]
| Contextual Adjacent Evidence | Wang 2026: Repeated Annual Influenza Vaccination in Older Adults Induces Comparable Seroprotection Despite Reduced Antibody Fold Rise: A 6-Month Prospective Cohort Study in China | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=21 extracted claim(s); source-level direction is the coded finding | [bundle:35]
| Contextual Adjacent Evidence | Wright 2025: Effectiveness of a theory-informed intervention to increase care home staff influenza vaccination rates: a cluster randomised controlled trial | direction=mixed | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=mixed | finding=representative non-significant statistic P = 0.435; not treated as positive or negative directional support unless source direction is coded | [bundle:12]
| Contextual Adjacent Evidence | Xie 2024: Impact of health education on promoting influenza vaccination health literacy in primary school students: a cluster randomised controlled trial protocol | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=5 extracted claim(s); source-level direction is the coded finding | [bundle:48]
| Contextual Adjacent Evidence | Zhang 2024: Influenza vaccination in patients with acute heart failure (PANDA II): study protocol for a hospital-based, parallel-group, cluster randomized controlled trial in China | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=9 extracted claim(s); source-level direction is the coded finding | [bundle:44]
| Dosing and Pharmacokinetics | Bonduelle 2025: Boosting effect of high-dose influenza vaccination on innate immunity among elderly | direction=unclear | directness=indirect | B2 | outcome=Dosing and Pharmacokinetics; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported | [bundle:40]
| Dosing and Pharmacokinetics | Bukhbinder 2026: Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination | direction=null | directness=indirect | B2 | outcome=Dosing and Pharmacokinetics; direction=null | finding=24 extracted claim(s); source-level direction is the coded finding | [bundle:31]
| Dosing and Pharmacokinetics | Wen 2025: Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years with or without previous influenza vaccination histories | direction=unclear | directness=indirect | B2 | outcome=Dosing and Pharmacokinetics; direction=unclear | finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded | [bundle:3]
| Frailty | Espersen 2025b: Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination Against Hospitalizations and Deaths According to Frailty Score: A Post Hoc Analysis of the DANFLU-1 Randomized Trial | direction=positive | directness=direct | A1 | outcome=Frailty; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:25]
| Immune and Inflammation | Abbasian 2025: Investigating the relationship between influenza vaccination and COVID-19 infection: a cohort study in Tehran | direction=unclear | directness=indirect | B2 | outcome=Immune and Inflammation; direction=unclear | finding=5 extracted claim(s); source-level direction is the coded finding | [bundle:47]
| Immune and Inflammation | Yingyounyong 2025: A study of booster dose influenza vaccination responses compared to standard dose in lupus patients: an open-labeled, randomized controlled study | direction=unclear | directness=direct | A1 | outcome=Immune and Inflammation; direction=unclear | finding=representative non-significant statistic P = 0.064; not treated as positive or negative directional support unless source direction is coded | [bundle:8]
| Longevity | Alotaibi 2026: Impact of Influenza Vaccination on Mortality and Major Cardiovascular Events in Adults with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | direction=mixed | directness=review | B1 | outcome=Longevity; direction=mixed | finding=representative statistic P = 0.004; source-level statistic reported | [bundle:34]
| Longevity | Appel 2025: The Effect of Influenza Vaccination on Hospitalization and Mortality Among People With Dementia | direction=positive | directness=indirect | B2 | outcome=Longevity; direction=positive | finding=44 extracted claim(s); source-level direction is the coded finding | [bundle:16]
| Longevity | Hosseini 2026: Mortality and Morbidity Benefit After Influenza Vaccination in High Cardiovascular Risk Population: A Systematic Review and Meta-analysis. | direction=positive | directness=review | B1 | outcome=Longevity; direction=positive | finding=4 extracted claim(s); source-level direction is the coded finding | [bundle:49]
| Longevity | Incalzi 2024: Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion | direction=null | directness=review | B2 | outcome=Longevity; direction=null | finding=2 extracted claim(s); source-level direction is the coded finding | [bundle:52]
| Longevity | Leung 2025: The effect of SARS-CoV-2 and influenza vaccination on endemic coronavirus-related mortality: A retrospective cohort study in Brazil | direction=positive | directness=indirect | B2 | outcome=Longevity; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:36]
| Longevity | Liu 2025: Association between influenza vaccination and prognosis in patients with ischemic heart disease: A systematic review and meta-analysis of randomized controlled trials. | direction=positive | directness=review | B1 | outcome=Longevity; direction=positive | finding=7 extracted claim(s); source-level direction is the coded finding | [bundle:45]
| Longevity | Luo 2026: Impacts of delayed influenza vaccination on clinical outcomes in ICU-admitted patients with influenza: A retrospective cohort study | direction=null | directness=indirect | B2 | outcome=Longevity; direction=null | finding=representative non-significant statistic P = 0.838; not treated as positive or negative directional support unless source direction is coded | [bundle:7]
| Longevity | Streeter 2022: Influenza vaccination reduced myocardial infarctions in United Kingdom older adults: a prior event rate ratio study. | direction=positive | directness=review | B1 | outcome=Longevity; direction=positive | finding=4 extracted claim(s); source-level direction is the coded finding | [bundle:50]
| Mortality and Survival | Sun 2025: Effect of Current-Season-Only Versus Continuous Two-Season Influenza Vaccination on Mortality in Older Adults: A Propensity-Score-Matched Retrospective Cohort Study | direction=positive | directness=indirect | B2 | outcome=Mortality and Survival; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:1]
| Safety and Comorbidity | Espersen 2025a: Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial fibrillation: a prespecified analysis of the NUDGE-FLU-CHRONIC trial | direction=positive | directness=indirect | B2 | outcome=Safety and Comorbidity; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:2]
| Safety and Comorbidity | Jiang 2025: Barriers to influenza vaccination in older adults with chronic diseases: Insights from a COM-B model–based meta-analysis | direction=null | directness=review | B2 | outcome=Safety and Comorbidity; direction=null | finding=31 extracted claim(s); source-level direction is the coded finding | [bundle:24]

**Thesis:** Across 53 curated reference papers, the evidence base for Influenza shows a context-dependent profile. Positive signals appear in: longevity, cardiometabolic. Null findings dominate: contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Influenza broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 53 included sources. By directness, the breakdown is: indirect (n=26), review (n=14), direct (n=12), protocol (n=1). 25 of 53 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: adults; type 2 diabetes patients; older adults; frail / sarcopenic adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus is dominated by indirect observational cohorts and review-level syntheses rather than primary randomized trials with hard clinical endpoints, which is the principal limitation shaping every downstream inference. No long-term mortality RCT enrolling non-diabetic community-dwelling adults under 65 with multi-season follow-up is represented, which means the headline claims about longevity benefits cannot rest on randomized evidence within this corpus and instead depend on indirect comparisons and umbrella-review pooling (Hosseini 2026, Liu 2025, Streeter 2022). Mechanistic or immunological endpoints are also over-represented in the direct stratum (immunogenicity, seroprotection, antibody titer rise), while functional orality, hospitalization-with-ICU admission, and cause-specific mortality are under-represented as standalone direct RCT outcomes. [bundle:45] [bundle:49] [bundle:50]

Several clinically attractive outcome claims rest on a single within-corpus data point and therefore cannot be internally replicated. Bukhbinder 2026, reporting lower Alzheimer dementia risk after high-dose versus standard-dose vaccination, is similarly a single observation. Each of these single-trial anchors risks a winner's-curse inflation of the effect estimate and cannot be triangulated against another independent within-corpus estimate of the same outcome, so directional consistency is undetermined. [bundle:31]

The populations actually enrolled limit how far findings travel. The corpus does not contain multi-region randomized data in pregnant women, immunocompromised hosts beyond lupus (Yingyounyong 2025), or healthy working-age adults, so generalizability beyond the enrolled settings is not empirically supported. [bundle:8]

Several endpoints that would close the clinical-inference loop were not measured in the included corpus. Confirmed-influenza laboratory outcomes are absent as a direct randomized endpoint; immunological surrogates (HAI titer rises, seroprotection rates) stand in but, as Ioannidis 2005 cautions, surrogate-association data do not guarantee hard-outcome validity. Pediatric functional endpoints, frailty progression as measured by gait speed, and dementia incidence beyond the single Bukhbinder 2026 high-dose comparison are likewise unmeasured. [bundle:31]

The mechanistic-to-clinical translation gap is visible in this corpus wherever immunological or trained-immunity findings are invoked to support a clinical claim. None of these mechanistic or immunogenicity findings is paired in the corpus with a hard-outcome randomized comparison within the same population; clinical effects therefore must be inferred cross-domain, which is the precise pattern the cross-study disagreements (including the direct vs. indirect contextual other pairings and the Alotaibi 2026 positive mortality signal vs. Luo 2026 and Incalzi 2024 null mortality pattern) were designed to flag rather than to dissolve. [bundle:7] [bundle:34] [bundle:52]

## Conclusion

Substantive conclusion for Influenza Vaccination Effects: the retained source set shows 53 sources across Contextual Adjacent Evidence admitted n=26, Cardiometabolic admitted n=10, Longevity admitted n=8, Dosing and Pharmacokinetics admitted n=3; receipt-level directions mixed=3, null=22, positive=13, unclear=15; leading source labels Chen 2025, Yingyounyong 2025, Wang 2025a. The paper does not establish standalone clinical actionability. [bundle:5] [bundle:8] [bundle:10]

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 53 included sources. Effect directions are null (n=22), unclear (n=19), positive (n=11), mixed (n=1), with 25 sources carrying source-traced p-values and 494 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

This bounded outcome-class conclusion maps to the Boundary-Condition Matrix and Quantitative Evidence Index: direct human endpoints set the interpretive ceiling, while indirect or biomarker evidence defines mechanism and transferability boundaries.

## What This Synthesis Adds

This synthesis maps 53 included sources on Influenza Vaccination Effects across 8 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the null vs positive between Incalzi 2024 and Alotaibi 2026 on longevity (severity 4/5), which defines the boundary condition future studies must test rather than smooth over. [bundle:34] [bundle:52]

Prior reviews in the corpus (Alotaibi 2026, Liu 2025, Streeter 2022, Hosseini 2026) emphasize convergent signals on Influenza Vaccination Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. [bundle:34] [bundle:45] [bundle:49] [bundle:50]

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 8 | mixed, null, positive | conflict-resolution gap |
| cardiometabolic | 0 | 10 | null, positive, unclear | direct interventional hard-endpoint gap |
| frailty | 1 | 0 | positive | replication gap |
| dosing and pharmacokinetics | 0 | 3 | null, unclear | direct interventional hard-endpoint gap |
| immune and inflammation | 1 | 1 | unclear | replication gap |
| mortality and survival | 0 | 1 | positive | direct interventional hard-endpoint gap |
| safety and comorbidity | 0 | 2 | null, unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 10 | 16 | null, positive, unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: conflict-resolution gap | 0 direct and 8 indirect sources; direction profile: mixed, null, positive |
| P2 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 10 indirect sources; direction profile: null, positive, unclear |
| P3 | frailty: replication gap | 1 direct and 0 indirect source; direction profile: positive |
| P4 | dosing and pharmacokinetics: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null, unclear |
| P5 | immune and inflammation: replication gap | 1 direct and 1 indirect sources; direction profile: unclear |

### Next-Study Design Recommendation

The next high-yield study for Influenza Vaccination Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Chen 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. [bundle:5]
- Yingyounyong 2025; tier=A1; directness=direct; endpoint=immune; direction=unclear; representative statistic=P = 0.008. [bundle:8]
- Wang 2025a; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. [bundle:10]
- Wright 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.042. [bundle:12]
- Espersen 2025b; tier=A1; directness=direct; endpoint=frailty; direction=positive; representative statistic=P < 0.001. [bundle:25]
- Wang 2024; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:28]
- Li 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:33]
- Hansen 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:38]
- Lin 2024; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:41]
- Katangwe-Chigamba 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.045. [bundle:43]

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Chen 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=69. [bundle:5]
- Yingyounyong 2025: outcome=immune; directness=direct; tier=A1; direction=unclear; claims=59. [bundle:8]
- Wang 2025a: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=56. [bundle:10]
- Wright 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=49. [bundle:12]
- Espersen 2025b: outcome=frailty; directness=direct; tier=A1; direction=positive; claims=31. [bundle:25]
- Wang 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=26. [bundle:28]
- Li 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=22. [bundle:33]
- Hansen 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=18. [bundle:38]
- Lin 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=14. [bundle:41]
- Katangwe-Chigamba 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=9. [bundle:43]
- Zhang 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=9. [bundle:44]
- Xie 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=5. [bundle:48]
- Alotaibi 2026: outcome=longevity; directness=review; tier=B1; direction=mixed; claims=21. [bundle:34]
- Liu 2025: outcome=longevity; directness=review; tier=B1; direction=positive; claims=7. [bundle:45]
- Hosseini 2026: outcome=longevity; directness=review; tier=B1; direction=positive; claims=4. [bundle:49]
- Streeter 2022: outcome=longevity; directness=review; tier=B1; direction=positive; claims=4. [bundle:50]
- Sun 2025: outcome=mortality survival; directness=indirect; tier=B2; direction=positive; claims=106. [bundle:1]
- Espersen 2025a: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=97. [bundle:2]
- Wen 2025: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=unclear; claims=93. [bundle:3]
- Guo 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=76. [bundle:4]
- Fortunato 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=68. [bundle:6]
- Luo 2026: outcome=longevity; directness=indirect; tier=B2; direction=null; claims=61. [bundle:7]
- Yang 2024: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=57. [bundle:9]
- Tadount 2025: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=52. [bundle:11]
- Szilagyi 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=47. [bundle:13]
- Wang 2025b: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=47. [bundle:14]
- Wang 2025c: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=46. [bundle:15]
- Appel 2025: outcome=longevity; directness=indirect; tier=B2; direction=positive; claims=44. [bundle:16]
- Jin 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=43. [bundle:17]
- Alshagrawi 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=34. [bundle:19]
- Rocinova 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=positive; claims=33. [bundle:20]
- Papagiannis 2024: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=32. [bundle:21]
- Jiang 2025: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=31. [bundle:24]
- Krishnan 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=31. [bundle:23]
- Wei 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=31. [bundle:22]
- Chaves 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=28. [bundle:26]
- Chiu 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=26. [bundle:27]
- Hu 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=26. [bundle:29]
- Alshahrani 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=25. [bundle:30]
- Andrew 2004: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=24. [bundle:53]

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 4 null vs positive: Incalzi 2024 vs Alotaibi 2026; Alotaibi 2026 (positive on mortality) vs Incalzi 2024 (null on mortality) — partial conflict [bundle:34] [bundle:52]
- Severity 4 null vs positive: Luo 2026 vs Alotaibi 2026; Alotaibi 2026 (positive on mortality) vs Luo 2026 (null on mortality) — partial conflict [bundle:7] [bundle:34]
- Severity 3 indirectness gap: Wang 2024 vs Hu 2024; Wang 2024 (direct, A1) vs Hu 2024 (indirect) on contextual other — direct vs indirect must be kept separate [bundle:28] [bundle:29]
- Severity 3 indirectness gap: Wang 2024 vs Papagiannis 2024; Wang 2024 (direct, A1) vs Papagiannis 2024 (review) on contextual other — direct vs indirect must be kept separate [bundle:21] [bundle:28]
- Severity 3 indirectness gap: Wang 2024 vs Alshagrawi 2025; Wang 2024 (direct, A1) vs Alshagrawi 2025 (review) on contextual other — direct vs indirect must be kept separate [bundle:19] [bundle:28]
- Severity 3 indirectness gap: Wang 2024 vs Mora 2025; Wang 2024 (direct, A1) vs Mora 2025 (indirect) on contextual other — direct vs indirect must be kept separate [bundle:28] [bundle:37]
- Severity 3 indirectness gap: Wang 2024 vs Szilagyi 2025; Wang 2024 (direct, A1) vs Szilagyi 2025 (indirect) on contextual other — direct vs indirect must be kept separate [bundle:13] [bundle:28]
- Severity 3 indirectness gap: Wang 2024 vs Wang 2025b; Wang 2024 (direct, A1) vs Wang 2025b (indirect) on contextual other — direct vs indirect must be kept separate [bundle:14] [bundle:28]

## Quantitative Evidence Index — influenza vaccination effects

_Quantitative Evidence Index: top 27 high-confidence numeric claims from the corpus. Every row traces to a corpus-bound claim and a registered citation._

**Numeric verification note:** P-values are rendered from extracted source statistics; rounded zero values are reported at their implied decimal floor rather than as impossible zero probabilities.

| Study | Endpoint | Arm | Value | Type | Statistic |
|---|---|---|---|---|---|
| Sun 2025 | mortality | influenza vaccination | HR = 0.61 | hazard ratio | — | [bundle:1]
| Liu 2025 | cardiovascular events | control | RR = 0.55 | risk ratio | — | [bundle:45]
| Liu 2025 | mortality | control | RR = 0.58 | risk ratio | — | [bundle:45]
| Hosseini 2026 | mortality | influenza vaccination | HR = 0.72 | hazard ratio | — | [bundle:49]
| Appel 2025 | mortality | — | HR: 0.85 | hazard ratio | — | [bundle:16]
| Hosseini 2026 | cardiovascular events | — | HR = 0.81 | hazard ratio | — | [bundle:49]
| Guo 2025 | cardiovascular events | influenza vaccination | — | 95%CI | (0.83–0.89) | [bundle:4]
| Alotaibi 2026 | mortality | influenza vaccination | — | 95%CI | (0.57–0.90) | [bundle:34]
| Alotaibi 2026 | cardiovascular events | influenza vaccination | — | 95%CI | (0.26–0.74) | [bundle:34]
| Jin 2026 | cardiovascular events | influenza vaccination | — | 95%CI | (0.52–0.87) | [bundle:17]
| Papagiannis 2024 | mortality | — | P = 0.015 | p-value | — | [bundle:21]
| Bonduelle 2025 | vaccine response | — | P < 0.05 | p-value | — | [bundle:40]
| Wang 2025c | body mass index | — | P > 0.05 | p-value | — | [bundle:15]
| Espersen 2025b | frailty | — | P < 0.001 | p-value | — | [bundle:25]
| Yingyounyong 2025 | vaccine response | influenza vaccination | 25% | % | — | [bundle:8]
| Dehesh 2025 | adverse events | influenza vaccination | 27% | % | — | [bundle:39]
| Wright 2025 | mortality | control | 55% | % | — | [bundle:12]
| Leung 2025 | mortality | influenza vaccination | 39% | % | — | [bundle:36]
| Guo 2025 | body mass index | control | 30% | % | — | [bundle:4]
| Yang 2025 | mortality | influenza vaccination | 10% | % | — | [bundle:42]
| Tadount 2025 | mortality | influenza vaccination | 67% | % | — | [bundle:11]
| Tadount 2025 | cardiovascular events | influenza vaccination | 33% | % | — | [bundle:11]
| Fortunato 2025 | inflammation | influenza vaccination | 34.5% | % | — | [bundle:6]
| Andrew 2004 | mortality | influenza vaccination | 55.2% | % | — | [bundle:53]
| Streeter 2022 | mortality | influenza vaccination | 95% | % | — | [bundle:50]
| Papagiannis 2024 | cardiovascular events | — | 2.9% | % | — | [bundle:21]
| Pedersen 2024 | blood glucose | — | 11.1 mmol/L | mmol/L | — | [bundle:18]

## References

- **Sun 2025.** _Effect of Current-Season-Only Versus Continuous Two-Season Influenza Vaccination on Mortality in Older Adults: A Propensity-Score-Matched Retrospective Cohort Study._ Vaccines, 2025. DOI: 10.3390/vaccines13020164 PMID: 40006711.
- **Espersen 2025a.** _Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial fibrillation: a prespecified analysis of the NUDGE-FLU-CHRONIC trial._ European Heart Journal Open, 2025. DOI: 10.1093/ehjopen/oeaf160 PMID: 41536962.
- **Wen 2025.** _Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years with or without previous influenza vaccination histories._ Human Vaccines & Immunotherapeutics, 2025. DOI: 10.1080/21645515.2025.2468074 PMID: 39993940.
- **Guo 2025.** _Estimating cardiovascular effects of influenza vaccination in older adults: a target trial emulation using proximal causal inference._ eClinicalMedicine, 2025. DOI: 10.1016/j.eclinm.2025.103449 PMID: 40896461.
- **Chen 2025.** _Impact of multifaceted health education on influenza vaccination health literacy in primary school students: a cluster randomized controlled trial._ BMC Medicine, 2025. DOI: 10.1186/s12916-025-04156-1 PMID: 40468328.
- **Fortunato 2025.** _Association of socio-economic and clinical factors with influenza vaccination uptake in high-risk individuals: an Italian retrospective cohort study, 2019–2023._ International Journal of Health Geographics, 2025. DOI: 10.1186/s12942-025-00446-2 PMID: 41455971.
- **Luo 2026.** _Impacts of delayed influenza vaccination on clinical outcomes in ICU-admitted patients with influenza: A retrospective cohort study._ Virus Research, 2026. DOI: 10.1016/j.virusres.2026.199700 PMID: 41643751.
- **Yingyounyong 2025.** _A study of booster dose influenza vaccination responses compared to standard dose in lupus patients: an open-labeled, randomized controlled study._ Clinical and Experimental Medicine, 2025. DOI: 10.1007/s10238-025-01639-6 PMID: 40205278.
- **Yang 2024.** _Influenza Vaccination Coverage and Influencing Factors in Type 2 Diabetes in Mainland China: A Systematic Review and Meta-Analysis._ Vaccines, 2024. DOI: 10.3390/vaccines12111259 PMID: 39591162.
- **Wang 2025a.** _A cluster randomised trial of digital messaging nudges to improve influenza vaccination uptake in China._ NPJ Digital Medicine, 2025. DOI: 10.1038/s41746-025-02137-5 PMID: 41310039.
- **Tadount 2025.** _Does influenza vaccination contribute to the prevention of cardiovascular events? An umbrella review._ Canada Communicable Disease Report, 2025. DOI: 10.14745/ccdr.v51i09a02 PMID: 41393795.
- **Wright 2025.** _Effectiveness of a theory-informed intervention to increase care home staff influenza vaccination rates: a cluster randomised controlled trial._ Journal of Public Health (Oxford, England), 2025. DOI: 10.1093/pubmed/fdaf023 PMID: 40158203.
- **Szilagyi 2025.** _Video and Infographic Messages From Primary Care Physicians and Influenza Vaccination Rates._ JAMA Network Open, 2025. DOI: 10.1001/jamanetworkopen.2025.26514 PMID: 40802184.
- **Wang 2025b.** _Effectiveness, Usability, and Acceptability of ChatGPT With Retrieval-Augmented Generation (SIV-ChatGPT) in Increasing Seasonal Influenza Vaccination Uptake Among Older Adults: Quasi-Experimental Study._ Journal of Medical Internet Research, 2025. DOI: 10.2196/76849 PMID: 40921067.
- **Wang 2025c.** _Influenza Vaccination and Short‐Term Risk of Stroke Among Elderly Patients With Chronic Comorbidities in a Population‐Based Cohort Study._ The Journal of Clinical Hypertension, 2025. DOI: 10.1111/jch.70044 PMID: 40751465.
- **Appel 2025.** _The Effect of Influenza Vaccination on Hospitalization and Mortality Among People With Dementia._ Journal of the American Geriatrics Society, 2025. DOI: 10.1111/jgs.19392 PMID: 40123175.
- **Jin 2026.** _Influenza vaccination and cardiovascular and respiratory outcomes in high-risk populations: an umbrella review of systematic reviews and meta-analyzes._ Frontiers in Immunology, 2026. DOI: 10.3389/fimmu.2026.1798398 PMID: 42273673.
- **Pedersen 2024.** _INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED): a study protocol for a randomised, double-blind, placebo-controlled clinical trial in children and adolescents with recent-onset type 1 diabetes._ BMJ Open, 2024. DOI: 10.1136/bmjopen-2024-084808 PMID: 38950997.
- **Alshagrawi 2025.** _Impact of COVID-19 pandemic on influenza vaccination rates among healthcare workers and the general population in Saudi Arabia: A meta-analysis._ Human Vaccines & Immunotherapeutics, 2025. DOI: 10.1080/21645515.2025.2477954 PMID: 40068961.
- **Rocinova 2026.** _Factors influencing the relationship between influenza vaccination and the risk of developing dementia: A systematic review._ Journal of Alzheimer's Disease, 2026. DOI: 10.1177/13872877261420240 PMID: 41736221.
- **Papagiannis 2024.** _Pneumococcal and Influenza Vaccination Coverage in Patients with Heart Failure: A Systematic Review._ Journal of Clinical Medicine, 2024. DOI: 10.3390/jcm13113029 PMID: 38892740.
- **Jiang 2025.** _Barriers to influenza vaccination in older adults with chronic diseases: Insights from a COM-B model–based meta-analysis._ Human Vaccines & Immunotherapeutics, 2025. DOI: 10.1080/21645515.2025.2574732 PMID: 41128133.
- **Espersen 2025b.** _Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination Against Hospitalizations and Deaths According to Frailty Score: A Post Hoc Analysis of the DANFLU-1 Randomized Trial._ The Journal of Infectious Diseases, 2025. DOI: 10.1093/infdis/jiaf420 PMID: 40796377.
- **Wei 2026.** _The benefits of influenza vaccination in patients with cardiovascular disease: a systematic review and meta-analysis._ Frontiers in Pharmacology, 2026. DOI: 10.3389/fphar.2025.1701127 PMID: 41640676.
- **Krishnan 2026.** _Burden of Influenza and Cost‐Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in India._ Influenza and Other Respiratory Viruses, 2026. DOI: 10.1111/irv.70264 PMID: 42062199.
- **Chaves 2026.** _Monitoring influenza vaccination coverage among older adults: a rural cohort study, Rio Grande, 2017-2022._ Epidemiologia e Serviços de Saúde : Revista do Sistema Unico de Saúde do Brasil, 2026. DOI: 10.1590/S2237-96222026v35e20250561.en PMID: 41880426.
- **Wang 2024.** _Nudging towards COVID-19 and influenza vaccination uptake in medically at-risk children: EPIC study protocol of randomised controlled trials in Australian paediatric outpatient clinics._ BMJ Open, 2024. DOI: 10.1136/bmjopen-2023-076194 PMID: 38367966.
- **Hu 2024.** _Effectiveness of Multifaceted Strategies to Increase Influenza Vaccination Uptake._ JAMA Network Open, 2024. DOI: 10.1001/jamanetworkopen.2024.3098 PMID: 38526493.
- **Chiu 2025.** _Big data analysis of influenza vaccination and liver cancer risk in hypertensive patients: insights from a nationwide population-based cohort study._ BMC Gastroenterology, 2025. DOI: 10.1186/s12876-025-03665-w PMID: 39994561.
- **Alshahrani 2025.** _Influenza Vaccination and Morbidity Among Sudanese Hajj Pilgrims During the 2025 Hajj._ Vaccines, 2025. DOI: 10.3390/vaccines13111134 PMID: 41295507.
- **Bukhbinder 2026.** _Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination._ Neurology, 2026. DOI: 10.1212/WNL.0000000000214782 PMID: 41921123.
- **McConeghy 2025.** _Recombinant vs Egg-Based Quadrivalent Influenza Vaccination for Nursing Home Residents._ JAMA Network Open, 2025. DOI: 10.1001/jamanetworkopen.2024.52677 PMID: 39745702.
- **Andrew 2004.** _Rates of influenza vaccination in older adults and factors associated with vaccine use: A secondary analysis of the Canadian Study of Health and Aging._ BMC Public Health, 2004. DOI: 10.1186/1471-2458-4-36 PMID: 15306030.
- **Li 2025.** _Effectiveness of pay it forward intervention compared to free and user-paid vaccinations on seasonal influenza vaccination among older adults across seven cities in China: study protocol of a three-arm cluster randomized controlled trial._ BMC Public Health, 2025. DOI: 10.1186/s12889-025-23301-2 PMID: 40610910.
- **Alotaibi 2026.** _Impact of Influenza Vaccination on Mortality and Major Cardiovascular Events in Adults with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials._ Vaccines, 2026. DOI: 10.3390/vaccines14040309 PMID: 42042785.
- **Wang 2026.** _Repeated Annual Influenza Vaccination in Older Adults Induces Comparable Seroprotection Despite Reduced Antibody Fold Rise: A 6-Month Prospective Cohort Study in China._ Vaccines, 2026. DOI: 10.3390/vaccines14040338 PMID: 42042813.
- **Leung 2025.** _The effect of SARS-CoV-2 and influenza vaccination on endemic coronavirus-related mortality: A retrospective cohort study in Brazil._ Human Vaccines & Immunotherapeutics, 2025. DOI: 10.1080/21645515.2025.2516314 PMID: 40497727.
- **Mora 2025.** _Determinants of influenza vaccination uptake among older adults in Catalonia using a longitudinal population study: the role of public health campaigns._ BMJ Public Health, 2025. DOI: 10.1136/bmjph-2025-002698 PMID: 40791265.
- **Hansen 2025.** _Effectiveness of Text Messaging Nudging to Increase Coverage of Influenza Vaccination Among Older Adults in Norway (InfluSMS Study): Protocol for a Randomized Controlled Trial._ JMIR Research Protocols, 2025. DOI: 10.2196/63938 PMID: 39998878.
- **Dehesh 2025.** _Influenza Vaccination and Cardiovascular Outcomes in Patients with Coronary Artery Diseases: A Placebo-Controlled Randomized Study, IVCAD._ Vaccines, 2025. DOI: 10.3390/vaccines13050472 PMID: 40432084.
- **Lin 2024.** _Promoting Influenza Vaccination Uptake Among Chinese Older Adults Based on Information–Motivation–Behavioral Skills Model and Conditional Economic Incentive: Protocol for Randomized Controlled Trial._ Healthcare, 2024. DOI: 10.3390/healthcare12232361 PMID: 39684983.
- **Bonduelle 2025.** _Boosting effect of high-dose influenza vaccination on innate immunity among elderly._ JCI Insight, 2025. DOI: 10.1172/jci.insight.184128 PMID: 40036077.
- **Yang 2025.** _Influenza vaccination and ischemic stroke risk reduction in elderly stroke survivors: a retrospective cohort study with negative control validation._ BMC Geriatrics, 2025. DOI: 10.1186/s12877-025-06695-x PMID: 41315989.
- **Zhang 2024.** _Influenza vaccination in patients with acute heart failure (PANDA II): study protocol for a hospital-based, parallel-group, cluster randomized controlled trial in China._ Trials, 2024. DOI: 10.1186/s13063-024-08452-8 PMID: 39587669.
- **Katangwe-Chigamba 2025.** _Process evaluation of the flucare cluster randomised controlled trial: assessing the implementation of a behaviour change intervention to increase influenza vaccination uptake among care home staff in England._ BMC Health Services Research, 2025. DOI: 10.1186/s12913-025-13298-0 PMID: 40835927.
- **Liu 2025.** _Association between influenza vaccination and prognosis in patients with ischemic heart disease: A systematic review and meta-analysis of randomized controlled trials._ Travel Med Infect Dis, 2025. DOI: 10.1016/j.tmaid.2024.102793 PMID: 39710016.
- **Pagkozidis 2026.** _Strategies to Enhance Seasonal Influenza Vaccination Uptake: Qualitative Insights from Primary Care Physicians in Greece._ Vaccines, 2026. DOI: 10.3390/vaccines14050458 PMID: 42188828.
- **Xie 2024.** _Impact of health education on promoting influenza vaccination health literacy in primary school students: a cluster randomised controlled trial protocol._ BMJ Open, 2024. DOI: 10.1136/bmjopen-2023-080115 PMID: 38609315.
- **Abbasian 2025.** _Investigating the relationship between influenza vaccination and COVID-19 infection: a cohort study in Tehran._ BMC Infectious Diseases, 2025. DOI: 10.1186/s12879-025-12392-2 PMID: 41449332.
- **Streeter 2022.** _Influenza vaccination reduced myocardial infarctions in United Kingdom older adults: a prior event rate ratio study._ J Clin Epidemiol, 2022. DOI: 10.1016/j.jclinepi.2022.06.018 PMID: 35817230.
- **Hosseini 2026.** _Mortality and Morbidity Benefit After Influenza Vaccination in High Cardiovascular Risk Population: A Systematic Review and Meta-analysis._ Am J Cardiol, 2026. DOI: 10.1016/j.amjcard.2026.03.040 PMID: 41951138.
- **Blandi 2026.** _From breath to brain: influenza vaccination as a pragmatic strategy for dementia prevention._ Aging Clinical and Experimental Research, 2026. DOI: 10.1007/s40520-026-03323-5 PMID: 41543642.
- **Incalzi 2024.** _Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion._ Internal and Emergency Medicine, 2024. DOI: 10.1007/s11739-023-03456-9 PMID: 37891453.

{
  "article_type": "evidence_map",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "31617e01-1221-485d-a693-8cab974deb50",
  "title": "Research Synthesis: Influenza Vaccination Effects \u2014 full paper"
}